Rehaler has been tested in a randomized, controlled, double-blind clinical trial on migraine with aura, which showed significantly higher user satisfaction and pain relief compared to placebo. 78% of attacks had pain relief already at the second treatment. Large follow-up studies are now in preparation, focusing on several different types of migraine.
The clinical trial of Rehaler was conducted by the Headache Clinic at Aarhus University Hospital in Denmark. The results of the study were in August 2018 published in Cephalalgia which is the highest-ranked scientific headache journal in the world. The article can be accessed for free here.
Rehaler received CE approval and entered the European market in 2018.
Henrik is a consultant neurologist, associate professor and migraine researcher at the Danish Headache Center at Copenhagen University Hospital, Denmark. He has published a large number of scientific articles in the fields of migraine, experimental headache models, headache diagnostics and the use of medical imaging in headache research. In 2015 he was awarded the Harold Wolff – John Graham award by the American Academy of Neurology for his research.
Parisa is an associate professor and pain researcher at the Department of Health Science and Technology at Aalborg University, Denmark. She has a large number of publications in the fields of migraine, pharmacological pain treatment and the physiology of pain. In addition, she is one of two scientists behind an innovative biomarker for migraine.
Anders is a neurologist and researcher at the Danish Headache Center at Copenhagen University Hospital, Denmark. He has done extensive research in the fields of migraine with aura, the use of medical imaging in headache research, and the significance of trigger factors in headache.